Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging

European Radiology

Volumn 21, Issue 6, 2011, Pages 1188-1199

  Fangberget, A ^a   Nilsen, L B ^b,c   Hole, K H ^a,c   Holmen, M M ^a   Engebraaten, O ^b,c   Naume, B ^a   Smith, H J ^b,c   Olsen, D R ^d   Seierstad, T ^b,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

ADC; Breast cancer; DCE MRI; Neoadjuvant chemotherapy; Prediction

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; GENE OVEREXPRESSION; HUMAN; IMAGE QUALITY; INTRADUCTAL CARCINOMA; LABORATORY DIAGNOSIS; LUNG CARCINOMA; LYMPH NODE; MAMMOGRAPHY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PARITY; POSTMENOPAUSE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PREMENOPAUSE; PRIORITY JOURNAL; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 79959206911     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-010-2020-3     Document Type: Article

References (30)

1. Mortality and Prevalence Worldwide (2004) IARC CancerBase No. 5, version 2.0. IARC, Lyon
2. Cancer Registry of Norway (2009) Cancer in Norway 2008 - Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway, Oslo
3. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Inst Monogr 30:96-102
4. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237 (Pubitemid 33081640)
5. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurements of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422 (Pubitemid 350013847)
6. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J Clin Oncol 26:778-785 (Pubitemid 351264391)
7. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C (2004) Locally advanced breast cancer comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14:1371-1379 (Pubitemid 39162217)
8. Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, Halpern E, Moore R, Kuter I, Taghian A (2005) Prospective comparison of mammography, sonography and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184:868-877 (Pubitemid 43899515)
9. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179:1193-1199 (Pubitemid 35204372)
10. Belli P, Constantini M, Malaspina C, Magistrelli A, Latorre G, Bonomo L (2006) MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 61:946-953 (Pubitemid 44464116)
11. Grimsby GM, Gray R, Amylou D, Carpenter S, Stucky C, Aspey H, Giurescu ME, Pockaj B (2009) Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am J Surg 198:500-504
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
13. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W (2001) Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume - a serial CT scan-based study. Int J Radiat Oncol Biol Phys 51:56-61 (Pubitemid 32758861)
14. Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, Regge D, Aglietta M (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83:67-76 (Pubitemid 38141894)
15. Mann RM, Kuhl CK, Kinkel K, Boetes C (2008) Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 18:1307-1318
16. Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Vrancken Peters M-J, Gilhuis KGA (2008) Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol 191:1331-1338
17. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW (2006) Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94:427-435 (Pubitemid 43237566)
18. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE (2006) Prediction of clinicopathological response of breast cancer to primary chemotherapy at contrast-enhanced MR-imaging: initial clinical results. Radiology 239:361-374
19. Luypaert R, Boujraf S, Sourbron S, Osteaux M (2001) Diffusion and perfusion MRI: basic physics. Eur J Radiol 38:19-27 (Pubitemid 32238182)
20. Iacconi C, Gianelli M, Marini C, Cilotti A, Moretti M, Viacava P, Picano E, Michelotti A, Caramella D (2010) The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study. Eur Radiol 20:303-308
21. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T (2010) Diffusion-weighted MRI for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 49:354-360
22. Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, Hatabu H, Kan S, Mountford C (2010) Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging - comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 254:357-366
23. Koh D-M, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622-1635 (Pubitemid 46866868)
24. Pickles MD, Gibbs P, Lowry M, Turnbull LW (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24:843-847 (Pubitemid 44205378)
25. Gibbs JE, Partridge SC, Hylton NM (2003) Incremental value of ADC as an indicator of treatment response in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Proc Intl Soc Magn Reson Med 11:291
26. Sharma U, Danishad KK, Seenu V, Jagannathan NR (2009) Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 22:104-113
27. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Bernstam FM, Valero V, Hortobagyi GN, Pusztai L (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25:1650-2655
28. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY (2008) MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 112:17-26
29. Bahri S, Chen J-H, Mehta RS, Carpenter PM, Nie K, Kwon S-Y, Yu HJ, Nalcioglu O, Su M-Y (2009) Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 16:1619-1628
30. Moon H-G, Han W, Lee JW, Ko E, Kim E-K, Yu J-H, Kang SY, Moon WK, Cho N, Park I-A, Oh D-Y, Han S-W, Im S-A, Noh DY (2009) Age and Her2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 20:636-641